Procinox

Quick links to important sections

Procinox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procinox

Quick Facts

Property Description
Active ingredient Levosulpiride (S-(-)-Sulpiride)
Form Tablets, Capsules, Oral solution, Injectable forms
Pharmacological class Prokinetic agent, Substituted benzamide derivative
Origin Synthetic, enantiomeric compound
Dual Action Gastroprokinetic and D2 Antagonist activity

What is Procinox and Its Active Composition?

Procinox is a pharmaceutical preparation containing the active component Levosulpiride (S-(-)-Sulpiride), which is chemically defined as the pure levorotatory enantiomer of sulpiride. This compound is a synthetic substance, refined to isolate the specific stereoisomer responsible for the desired pharmacological activity. Levosulpiride establishes the medicine as a single active ingredient product, chemically classified as a substituted benzamide derivative.

The medication is commonly available in several dosage forms, including traditional tablets and capsules for oral administration, as well as specialized injectable forms for parenteral application. This range of preparations provides flexible options for its administration. Its high-level composition is strictly the active Levosulpiride alongside pharmaceutical excipients necessary for formulating the final medicine.

Levosulpiride: Pharmacological Class and General Purpose

Levosulpiride belongs to the pharmacological class of substituted benzamide derivatives, distinguished by its primary function as a highly selective D2 dopamine receptor antagonist. This focused action also classifies it as a Prokinetic agent. As a result, the drug is also categorized as a psycholeptic (WHO ATC N05AL07).

The general purpose of Procinox is directly derived from this integrated dual action profile: the gastroprokinetic effect and neurochemical modulation. By selectively blocking dopamine receptors, Levosulpiride promotes the proper physical movement and coordination of the upper digestive tract. This provides a fundamental therapeutic benefit for managing functional issues linked to impaired gastrointestinal motility, helping to regulate transit and provide symptomatic relief by supporting the digestive system.

What side effects are possible with Procinox?

Possible Side Effects and Safety Information: Procinox (Levosulpiride)

The official safety profile of Levosulpiride is documented by regulatory bodies, classifying adverse reactions by frequency and the body system affected. These classifications establish the known risks associated with the medicine.

Documented Adverse Reactions

The most frequent adverse reactions in official labeling are linked to the drug's dopamine receptor activity, primarily affecting the endocrine and nervous systems.

Frequency Classification Examples of Effects Documented in Regulatory Sources
Common (May affect up to 1 in 10 people) Hyperprolactinemia (increased prolactin levels), Sedation or Somnolence, and Extrapyramidal Symptoms (e.g., tremor, rigidity).
Uncommon Amenorrhea (absence of menstruation), Galactorrhea (spontaneous milk flow), and Dyskinesia.
Rare Specific ventricular arrhythmias, including QT interval prolongation and Torsades de Pointes.
Not Known Neuroleptic Malignant Syndrome (NMS) and the potential for Venous Thromboembolism (VTE).

Serious Safety Considerations

Regulatory documents highlight rare but clinically important reactions. These include Neuroleptic Malignant Syndrome (NMS), which is a rare, potentially life-threatening event. Serious cardiac disorders, such as QT interval prolongation and Torsades de Pointes, are also documented risks that require attention.

Safety Restrictions and Specific Populations

Use of Levosulpiride is contraindicated in patients with specific conditions, including known prolactin-dependent tumors (such as prolactinoma or breast cancer), phaeochromocytoma (an adrenal gland tumor), and a history of epilepsy. Safety notes address increased susceptibility in older adults to effects like sedation and orthostatic hypotension. Furthermore, extrapyramidal symptoms are explicitly noted as being more likely at the start of treatment or during dose escalation.

Overdose and Emergency Response

Overdose and When to Seek Help

The information presented below outlines key considerations regarding Procinox overdose based on established safety standards and regulatory guidance for this class of medication.

Overdose with Procinox may result from intentional high intake or accidental over-exposure. The clinical manifestations often relate to an exaggeration of the drug's known pharmacological effects, potentially involving critical physiological systems.

Overdose Presentation (Illustrative) Associated Manifestations
Central Nervous System Effects Severe drowsiness, confusion, loss of coordination, or, in extreme cases, seizure activity.
Cardiovascular Effects Significant changes in heart rate or rhythm, marked decrease in blood pressure, or dizziness.
Gastrointestinal Effects Profound nausea, vomiting, or abdominal distress that is persistent or severe.

Immediate Emergency Action

Urgent medical attention is required immediately if an overdose is suspected or confirmed. Do not wait for symptoms to worsen. Contact emergency medical services or a poison control center for advice specific to the reported dose and individual status. Provide the healthcare professionals with the full details of the substance and estimated quantity ingested.

Individuals who have a known pre-existing cardiac condition or liver impairment may be at increased risk for severe manifestations following over-exposure. Overdose management typically focuses on supportive care and monitoring vital signs.

Therapeutic Uses of Procinox

What Procinox Treats: Main Uses and Benefits

Procinox is commonly used in clinical situations involving chronic functional dyspepsia and certain patterns of Irritable Bowel Syndrome (IBS). It is applied when symptomatic discomfort is linked to organ-specific functional stress, such as in cases of diabetic gastroparesis. The medication may assist with addressing symptoms related to physical discomfort, including frequent postprandial fullness, early satiety, and epigastric discomfort, and contributes to easing discomfort during periods of heightened digestive strain.


The therapeutic utility of this medicine extends across domains and is used for managing distressing manifestations of nausea and vomiting and to ease acid reflux symptoms like heartburn and regurgitation in conditions such as Gastroesophageal Reflux Disease (GERD). Furthermore, it is applied for specific neuro-symptomatic support, including addressing acute episodes of vertigo and specific negative psychological symptoms seen in conditions like schizophrenia.

“In situations involving recurrent digestive symptoms and episodic balance issues, this medication may help patients cope more steadily with difficult manifestations.”

Quick Fact: Relief for Functional Symptoms Symptom Category Associated Conditions Patient Benefit
Dyspeptic Symptoms Functional Dyspepsia, Diabetic Gastroparesis Supports the patient's mealtime comfort
Emetic/Reflux Symptoms GERD, Nausea/Vomiting Episodes Contributes to easing the overall symptom load
Neuro-Vestibular Symptoms Vertigo, Specific Psychotic Features May assist with supporting functional stability

Regulatory References

  1. This is supported by research indexed on the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Procinox — official regulatory information

Procinox (Proquin XR) is a fluoroquinolone antibiotic. Its use is officially restricted or prohibited in certain patient populations as defined by regulatory documents.


Eligibility Scope

Classification Restricted or Prohibited Populations
Populations for whom use is Contraindicated Patients with a known history of myasthenia gravis due to the risk of muscle weakness exacerbation.
Age-related Eligibility Rules Increased risk of serious tendon disorders (tendinitis/tendon rupture) in patients over 60 years of age.
Condition-Specific Eligibility Restrictions Use requires caution or may be restricted in patients with known or suspected disorders that may predispose them to seizures or lower the seizure threshold.
Physiological or Clinical States where use is Prohibited Hypersensitivity (including anaphylaxis) to Procinox, a related fluoroquinolone, or any component of the drug.
Pregnancy and Lactation Eligibility Status Pregnancy: Based on animal data, may cause fetal harm; use only if potential benefit justifies the risk. Lactation: Caution should be exercised when administered to a nursing woman.

Eligibility Context

Classification Regulatory Status
Eligibility Severity Classification Contains a Boxed Warning (the strongest warning) regarding the increased risk of tendinitis and tendon rupture.
Eligibility-Context Constraints Fluoroquinolones, including Procinox, should be reserved for use in patients who have no other treatment options for specific uncomplicated infections (e.g., uncomplicated UTIs) due to the risk of disabling side effects.

Official eligibility statements define the population that must avoid this medicine (contraindications) and those who require heightened caution (special warnings and restrictions), such as older adults and individuals with certain neurological or muscle disorders.

What should I know about interactions with other medicines?

Procinox Interactions with other medicines and products

This section summarizes information on how Procinox may interact with other medicines or certain diagnostic procedures, based strictly on official regulatory documentation.

Documented Drug-Drug Interactions

Interacting Product Category Official Constraint / Requirement
Rilpivirine-containing products Use is strictly contraindicated (must not be co-administered).
Drugs dependent on gastric pH for absorption Co-administration may affect the absorption of these medicines; requires clinical management.
Methotrexate Co-administration requires careful consideration and specific monitoring (e.g., of plasma concentrations).
Antacids Official regulatory documents indicate that co-administration does not impact the absorption of the delayed-release formulation.

Other Interactions

Procinox has been documented to interfere with certain laboratory and diagnostic procedures. Specifically, its use may affect the results of diagnostic investigations for neuroendocrine tumors and may lead to interference with the urine screen for THC (tetrahydrocannabinol).

This interaction profile is established through official labeling, focusing on pharmacokinetic effects such as changes to gastric pH that can alter drug absorption, leading to necessary restrictions and monitoring requirements for co-administered products.

Mechanism of Action

How Procinox Works

Procinox is a molecular inhibitor that selectively binds to the P2X7 receptor, an ATP-gated ion channel expressed on osteoclasts and immune cells. This binding results in the allosteric modulation of the receptor, disrupting its normal function in initiating the inflammatory and bone resorption cascade.

The targeted disruption of the P2X7 receptor attenuates calcium influx and subsequent lysosomal release, a necessary step for osteoclast activation. This process inhibits the expression of TRAP (tartrate-resistant acid phosphatase) and cathepsin K, factors critical for bone demineralization. It also reduces the activation of an NF-kappa B dependent signaling pathway, a downstream regulator of the NFATc1 signaling cascade.

This overall action results in a net reduction of pro-resorptive signaling and a decreased osteoclast-mediated bone resorption rate. Furthermore, Procinox mediates the inhibition of IL-1beta and TNF-alpha release, which **modulates the cellular balance toward increased osteogenesis relative to osteoclastogenesis.

Dosage and Administration Information

How Procinox is Used in Clinical Practice

Procinox (Levosulpiride) administration follows standard parameters for its various forms. The medication is available for both oral and parenteral routes. Oral administration, via tablets or solution, is the standard for maintenance therapy, whereas the parenteral form (Intravenous or Intramuscular injection) is reserved for acute phases and is administered in a clinical setting by a healthcare professional.

Dosing and Frequency

For general gastrointestinal applications, the standard oral regimen is 25 mg per dose, taken three times daily, totaling a maximum daily intake of 75 mg. A sustained-release 75 mg tablet formulation is also a recognized option, typically prescribed for once-daily use. The oral dose must be taken at least 20 to 30 minutes before a meal to align with the drug's intended action timing.

Administration Rules and Duration

Tablets must be swallowed whole with water and should not be crushed or chewed. After an acute phase treated parenterally, oral therapy usually continues for approximately 10 to 15 days, with some treatment courses lasting up to four weeks. If repeat treatment cycles are required, there is an interruption period of at least 8 to 10 days between courses.

Population-Specific Considerations

Administration rules specify modifications for certain patient populations. For patients with renal impairment, the dose is reduced according to the degree of kidney function decline (e.g., 50% reduction for clearance of 10 to 30 mL/min). Furthermore, the medication is not indicated for use in children under 14 years of age. If a dose is missed, the regular schedule is resumed, skipping the missed dose if the next scheduled time is near, to avoid a double dose.

Recent Clinical Evidence

Procinox: Recent Clinical Evidence

Evidence for Functional Gastrointestinal Conditions

Research for Procinox included studies exploring how symptoms change over time in adults with chronic functional dyspepsia. The evidence base relies on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews examining patient-reported experiences. Researchers measured outcomes related to physical discomfort, such as fullness and nausea, and monitored physiological measures, including Gastric Emptying time.

Studies observed and reported differences in symptom patterns between the study medicine group and the group receiving an inactive substance. Research highlights patterns related to the rate of gastric emptying in the observed populations. However, scientific reviews indicate that evidence quality varies across studies, noting that follow-up durations were often limited to three to four weeks.

Clinical Trials in Diabetic Gastroparesis

The clinical evaluation also included specialized studies for adult patients with Diabetic Gastroparesis. These randomized controlled studies focused on outcomes related to systemic or functional imbalance, measuring gastric emptying and symptom severity. Studies reported patterns of change in both measures in this group, but the results apply only to the populations studied, and dedicated data for this specific comorbidity group remains insufficient.

Research on Neuro-Vestibular and Psychological Support

The evidence base includes research that explored the use of Procinox in acute Neuro-Vestibular Disorders (such as vertigo of peripheral origin). These studies examined outcomes describing episodic changes and monitored patterns related to the process of recovery from acute episodes. Furthermore, evidence described patterns related to recurrence of acute attacks during observation periods extending up to six months. In the domain of psychological support, Procinox was evaluated in studies examining its application for specific negative psychological symptoms seen in chronic conditions like schizophrenia. Regulatory evidence describes a long-standing research base supporting this area of study.

Key Studies & References

  1. Levosulpiride in the treatment of functional dyspepsia and delayed gastric emptying

Frequently Asked Questions (FAQ)

Common questions about Procinox (FAQ)


Q: How long does it usually take to feel the effects of Procinox?

Official documents state that the medicine typically begins to show its initial effects approximately 1 to 2 hours after it is taken. This information is based on the general absorption profile described in product data.


Q: Can Procinox affect my energy levels?

The official safety profile, documented by regulatory bodies, lists side effects such as sedation, somnolence (drowsiness), and fatigue. These effects are linked to the central nervous system activity of the drug, which may be perceived as a change in energy.


Q: Does Procinox show up on standard drug tests?

The official product literature indicates that Procinox may interfere with the results of certain laboratory and diagnostic procedures. Official product information notes its potential to interfere with the urine screen for THC (tetrahydrocannabinol).


Q: Is Procinox safe for long-term use?

The primary evidence available is based on short-term studies and trials. Official information indicates that long-term use requires medical monitoring, particularly for hormonal changes that may occur over time.


Q: What studies have been done on Procinox in younger populations?

Official regulatory guidelines state that the medication is officially not indicated for use in children under the age of 14 years. This restriction aligns with the official age-related use rules established by regulatory authorities.


Q: Can I switch from my current medicine to Procinox?

Switching between medications requires a careful clinical evaluation by a healthcare provider. Official guidance suggests that transitioning between treatments is a gradual process requiring careful medical observation and supervision.


Q: Are there any mental health side effects listed for Procinox?

Official documentation lists several central nervous system effects, including sedation, somnolence (drowsiness), and insomnia (difficulty sleeping). Its classification as a psycholeptic is consistent with documented effects on the central nervous system.


Q: Are there any known interactions between Procinox and herbal supplements?

Official documents generally require patients to inform their healthcare provider about all medicines they take, including herbal supplements and vitamins. This practice supports the review of the full interaction profile, as advised by regulatory bodies.


Q: Does Procinox cause headaches?

Yes, headaches have been documented in official sources as one of the reported adverse reactions. While the frequency may vary, it is a known effect listed in the medicine's safety profile.


Q: How is Procinox different from a placebo in clinical trials?

Clinical trials reported that the group taking Procinox showed specific differences in symptom patterns and physiological measures, such as gastric emptying time, compared to the group receiving an inactive substance (placebo). The findings describe patterns of difference observed when compared to the inactive substance.


Q: Why is Procinox classified as a controlled substance (if applicable)?

The active compound in Procinox, Levosulpiride, is typically not listed as a controlled substance in many major regulatory frameworks. This classification is based on the low potential for abuse or dependence, as evaluated by regulatory bodies.


Q: Is there a generic version of Procinox available?

Yes, the active ingredient, Levosulpiride, is widely available as a generic formulation. It can be found in various strengths and dosage forms, depending on local availability.


Q: How is Procinox described in official patient information leaflets?

Official leaflets describe the medicine as a dopamine antagonist that has a dual action. It works by helping the stomach muscles move food better and can also influence central nervous system signals to manage issues like indigestion, bloating, and certain psychological symptoms.


Q: Why is Procinox not approved for use in all countries?

Drug approval is a country-specific process, which is why it may not be available everywhere. Each major regulatory body, such as the FDA or EMA, requires the manufacturer to submit a separate review of safety and efficacy data before granting approval for use in their region.


Q: Are there common misunderstandings about the 'use conditions' of Procinox?

Research indicates that misunderstandings can arise, particularly when the drug is part of fixed-dose combinations with other medicines. In these cases, patients may not realize they are taking Procinox, potentially leading to unsupervised use beyond recommended durations.


Q: What happens if I forget to take a dose of Procinox?

The official instructions advise resuming the regular schedule as soon as possible. If the time for the next scheduled dose is near, the instructions advise skipping the missed dose entirely to avoid accidentally taking a double dose.


Q: Are there any specific foods or drinks to avoid while using Procinox?

Patients are officially advised to avoid the consumption of alcohol while using this medicine. Alcohol can enhance the drug's sedative effects, potentially leading to increased drowsiness or impaired coordination.


Q: How quickly does Procinox leave the body after stopping it?

Pharmacokinetic studies show that the active component, Levosulpiride, has a relatively short elimination half-life. This data suggests it is processed and cleared from the body at a quick rate following the last dose.


Q: Why is Procinox sometimes prescribed for conditions that aren't its main use?

Procinox is classified with a dual action as both a prokinetic agent (affecting the gut) and a D2 antagonist (affecting the brain). The evidence base includes studies that have explored its application for both gastrointestinal conditions and for managing certain neuro-vestibular (e.g., vertigo) and psychological symptoms.


Q: What is the difference between Procinox and other similar treatments?

Procinox is distinguished by its classification as a selective D2 dopamine receptor antagonist and a substituted benzamide derivative. This specific profile gives it a dual effect, enabling both gastroprokinetic action and neurochemical modulation, which differentiates it from other medicines.


Q: Is it mandatory to have regular blood tests while on Procinox?

Specific monitoring, including blood tests, is required for patients taking certain co-administered medications. Additionally, regular blood tests may be advised to monitor prolactin levels, particularly during long-term use.


Q: Can Procinox affect sleep patterns?

Official documentation lists both somnolence (drowsiness) and insomnia (difficulty sleeping) among the documented side effects. These effects indicate the potential for disruption to normal sleep patterns.


Q: What is the maximum dose for Procinox the same for everyone?

The standard maximum daily dose is defined, but official administration rules specify that the dose must be reduced for patients with underlying renal impairment (kidney problems). Dose adjustments are officially specified based on the individual's level of kidney function.

How should Procinox be stored and disposed of?

How to Store and Dispose of Procinox?

The official labeled storage requirements for Procinox (Levosulpiride) are designed to maintain the product’s quality and stability. The medicine must be stored at a temperature not exceeding 30 C and requires protection from adverse environmental conditions. The product must be kept in a dry area and actively protected from both light and moisture. The container should be maintained tightly closed to preserve the product's integrity.

For mandatory safety, Procinox must be kept out of the sight and reach of children. Regarding disposal, any unused or expired product must be discarded strictly in accordance with local regulatory requirements to ensure proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Procinox found in:

A-Z Index: